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Objective. Currently, there are no reliable biomark-
ers for predicting therapeutic response in patients with
rheumatoid arthritis (RA). The synoviummay unlock criti-
cal information for determining efficacy, since a reduction
in the numbers of sublining synovial macrophages
remains the most reproducible biomarker. Thus, a clini-
cally actionable method for the collection of synovial tissue,
which can be analyzed using high-throughput strategies,
must become a reality. This study was undertaken to assess
the feasibility of utilizing synovial biopsies as a precision
medicine–based approach for patients with RA.
Methods. Rheumatologists at 6 US academic sites
were trained in minimally invasive ultrasound-guided
synovial tissue biopsy. Biopsy specimens obtained from
patients with RA and synovial tissue from patients with
osteoarthritis (OA) were subjected to histologic analysis,
fluorescence-activated cell sorting, and RNA sequencing
(RNA-seq). An optimized protocol for digesting synovial
tissue was developed to generate high-quality RNA-seq
libraries from isolated macrophage populations. Associa-
tions were determined between macrophage transcrip-
tional profiles and clinical parameters in RA patients.
Results. Patients with RA reported minimal ad-
verse effects in response to synovial biopsy. Comparable
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RNA quality was observed from synovial tissue and iso-
lated macrophages between patients with RA and
patients with OA. Whole tissue samples from patients
with RA demonstrated a high degree of transcriptional
heterogeneity. In contrast, the transcriptional profile of
isolated RA synovial macrophages highlighted different
subpopulations of patients and identified 6 novel tran-
scriptional modules that were associated with disease
activity and therapy.
Conclusion. Performance of synovial tissue biop-
sies by rheumatologists in the US is feasible and gener-
ates high-quality samples for research. Through the use
of cutting-edge technologies to analyze synovial biopsy
specimens in conjunction with corresponding clinical
information, a precision medicine–based approach for
patients with RA is attainable.
Despite the many therapies available for patients
with rheumatoid arthritis (RA), there is little information
to guide selection of the most effective treatment for an
individual patient. Forty-six percent of patients with RA
respond (defined as 50% improvement based on the
American College of Rheumatology criteria [ACR50]) to
conventional disease-modifying antirheumatic drugs
(DMARDs) (1,2) or conventional DMARDs plus anti–
tumor necrosis factor (anti-TNF) therapy (3–11). How-
ever, 20–40% of patients in clinical trials never demon-
strate even a minimal response (never meet the ACR20
response criteria) (7–11). Based on a population of >300
million in the US, a disease prevalence of 0.6%, and a
course of 3–4 months per biologic DMARD therapy, as
much as $2.5 billion is wasted annually on inadequate
therapy (12,13). There is a clear need to develop preci-
sion-based therapy for patients with RA, whereby clinical
information such as novel biomarkers will enhance our
ability to predict the therapeutic response and thereby
limit ineffective therapy.
Previous studies have linked macrophages to the
pathogenesis of RA. Synovial macrophages are highly acti-
vated, express elevated levels of Toll-like receptor 2 (TLR-
2), TLR-4, and TLR-7 (14,15), and contribute directly and
indirectly to synovial inflammation and the destruction of
cartilage and bone through the production of degradative
enzymes, cytokines, and chemokines. Further, TLR-2,
TLR-3, and TLR-7 play essential roles in the development
of inflammatory arthritis in mice (16–18). More impor-
tantly, macrophages are the central producers of inter-
leukin-1b (IL-1b), IL-6, and TNF, which comprise the 3
essential proinflammatory cytokines that contribute to RA
pathogenesis. To date, approved therapies, including anti-
TNF, anti–IL-6, JAK inhibitors, CTLA-4Ig, and anti-
CD20, have all been shown to decrease synovial inflamma-
tion and bone destruction and, more importantly, reduce
macrophage numbers in the synovial sublining (19–21).
Despite the fact that synovial macrophages were discovered
more than a half-century ago and are crucial for RA patho-
genesis (22), surprisingly very little is known about them.
Biomarkers that indicate sensitivity or resistance
to a particular therapy are sorely lacking in RA. For the
most part, researchers have used peripheral blood, with
minimal success, to identify biomarkers for predicting a
response to therapy (23). Similarly, the results of genetic
approaches have been disappointing (24). More recent
studies suggest that the synovium, as the target organ in
RA, may have greater potential in determining therapeu-
tic response (23). Currently, the most well-known and
reproducible biomarker for response to RA therapy is a
reduction in the number of sublining synovial macro-
phages, determined by immunohistochemical analysis of
synovial tissue (25). While arthroscopy has been the most
commonly used method to obtain synovial tissue before
and after therapy (26–32) and yields substantial amounts
of synovial tissue, it is invasive, requires surgical suites,
and is expensive, thus limiting its usefulness in clinical
practice and clinical studies. Synovectomy and joint
replacement surgery are other common mechanisms for
researchers to obtain synovial tissue, but patients under-
going these procedures typically exhibit end-stage disease
characteristics and samples likely do not reflect the over-
all pathophysiology at the time when therapeutic deci-
sions are made, prior to progressive joint damage.
Ultrasound technology has advanced significantly
and is widely used by rheumatologists as a mechanism for
determining the degree of synovitis and inflammation,
detecting erosions, and identifying sites for therapeutic
injection (33). Over the past decade, ultrasound has been
used to facilitate the collection of synovial tissue (29).
Minimally invasive ultrasound-guided synovial tissue biop-
sies have been performed for research purposes through-
out Europe, and the standardization for these procedures
has been fully evaluated (23,29,34–46). However, there
are currently no published studies from the US describing
the use of ultrasound-guided synovial tissue biopsies for
research. The potential reasons that this technique has
not been commonly adopted for research in the US
include a lack of training, differences in the medical sys-
tem and patient populations between Europe and the US,
and a lack of “buy-in” from rheumatologists who would
recommend the procedure to their patients.
We assembled a consortium of established aca-
demic rheumatology groups in the US, including the
University of Alabama at Birmingham, Columbia Univer-
sity, Mayo Clinic, Washington University, University of
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Michigan, and Northwestern University, to form the
RhEumatoid Arthritis SynOvial tissue Network (REA-
SON). Our consortium was trained in minimally invasive
ultrasound-guided synovial biopsy techniques in the UK
and has since performed more than 41 biopsies on RA
patients with active disease in the US. RNA was extracted
from whole synovial tissue and from synovial macro-
phages isolated by fluorescence-activated cell sorting
(FACS) for RNA sequencing (RNA-seq) analysis. The
transcriptional profiles of isolated macrophages were used
to distinguish between RA patient groups and identify
modules of co-regulated genes that were associated with
clinical disease and medication. We believe that these
studies demonstrate the utility of isolating individual pop-
ulations of cells within the synovium to understand the
pathobiology of the disease and to establish a precision
medicine–based approach for RA patients.
PATIENTS AND METHODS
Patients. Adult patients with RA, diagnosed according
to either the ACR 1987 criteria (47) or ACR/European League
Against Rheumatism 2010 criteria (48), were selected as candi-
dates for ultrasound-guided synovial biopsy based on the pres-
ence of palpable synovitis documented by clinical examination
(49,50). To increase the uniformity of the collected tissue, only
wrists were sampled in this study. Candidate joints were scanned
with standard 2-dimensional B-mode ultrasound with and with-
out Doppler (SonoSite M-MSK with a 15–6 MHz linear probe;
FujiFilm SonoSite), and were included in the study if they had a
grayscale synovitis score of ≥2 on a 4-point scale (35). Exclusion
criteria included uncontrolled comorbid diseases, anticoagula-
tion therapy (low-dose aspirin and nonsteroidal antiinflamma-
tory drugs [NSAIDs] were allowed), use of systemic steroids in
excess of prednisone 10 mg daily or equivalent, administration
of intramuscular steroids within the previous 4 weeks or intra-
articular steroids into the target joint within the past 8 weeks,
chronic or recurrent infection, intolerance to lidocaine or
chlorhexidine, inability to communicate effectively in English,
and membership in a vulnerable population (prisoners, pregnant
women, etc.).
Training for ultrasound-guided synovial biopsy. The
REASON consortium was created to adopt ultrasound-guided
synovial biopsy for research purposes in the US. Rheumatolo-
gists from REASON who were experienced in ultrasonography
traveled to the UK for a 2-day training session with Drs. Andrew
Filer, Christopher D. Buckley, Stephen Kelly, and Costantino
Pitzalis on ultrasound-guided synovial biopsy. This session
included observation of ultrasound-guided synovial biopsies fol-
lowed by a practice session using cadavers. Following the train-
ing session, the rheumatologists from REASON attended 2
additional practice sessions using cadavers at Northwestern
University for refresher training.
Ultrasound-guided synovial biopsy procedure. Proce-
dures were performed either in examination rooms in outpatient
rheumatology clinics or in a designated research space. After the
presence of synovitis was re-confirmed by sonographic criteria as
described above using customary non-sterile techniques, patients
were dressed in a laboratory cover-up or examination gown, sur-
gical mask, and surgical hair net. Rheumatologists performing
the biopsy were in surgical scrubs with cap, mask, sterile surgical
gown, and sterile gloves. The ultrasound probe was placed in a
sterile cover. The patient’s hand and arm were scrubbed with
chlorhexidine from the fingertips to the mid-forearm, and the
patient then placed the hand palm down onto a surgical wrist
support in a prepared sterile field. The arm was draped in a ster-
ile manner with a fenestrated sheet centered on the wrist, and
sterile ultrasound gel was applied.
Ultrasound scanning over the dorsal aspect of the wrist
joint in both the longitudinal and transverse planes was then
used to locate the region of greatest synovitis in the wrist, usually
immediately dorsal/superficial to either the proximal or the dis-
tal row of carpal bones. A wheal of lidocaine was used to anes-
thetize the skin at the ulnar aspect of the wrist. While
monitoring the procedure under ultrasound in real time with the
probe in the transverse position, an initial ultrasound-guided
lidocaine pass into the target joint was made with a 25-gauge 9
1.5-inch needle. A second ultrasound-guided lidocaine pass was
made into the same wound and needle track with an 18-gauge 9
1.5-inch needle to ensure anesthesia and a clear path for the
biopsy device. Care was taken to avoid neurovascular structures
and tendons, especially the extensor digiti minimi. An appropri-
ately sized Quick-Core Biopsy needle (Cook Medical) was then
selected based on the target wrist (usually 18 gauge 9 9 cm, with
10-mm throw) and introduced into the same needle track.
Using continuous real-time ultrasound imaging, the jaw
of the device was positioned within the synovium (defined by
Outcome Measures in Rheumatology [51] as intraarticular,
hypoechoic, non-displaceable, poorly compressible tissue) at the
point of its greatest abundance, usually between the common
extensor tendon bundle and the underlying carpal row. The
device was triggered and removed. The sample was removed
from the device by scraping with a sterile 21-gauge needle and
placed into phosphate buffered saline (PBS) (Thermo Fisher).
The process was repeated to obtain a total of 12 samples. Not all
biopsy passes yielded tissue; most procedures resulted in 1–3
“empty passes,” and thus most patients underwent a total of 13–
15 passes to obtain 12 samples of synovium. All samples were
taken through the same skin wound but with varying positions of
the jaw of the device within the region of most abundant synovi-
tis, with the intent of sampling the entire chosen region uni-
formly. Variations in the position of the device also included
variations in the radial orientation of the jaw with respect to the
axis of the device. For example, some samples were taken from
12 o’clock, closer to the extensor tendon bundle, and some from
6 o’clock, closer to the carpal row.
At the completion of the procedure the biopsy site was
washed, and after confirming hemostasis, an adhesive bandage
was applied to the single puncture wound. None of the patients
needed a suture. Patients were instructed in routine after-care
and encouraged to use over-the-counter acetaminophen for any
discomfort, with permission to escalate to over-the-counter
NSAIDs if needed. Patients were instructed to contact the
research team by telephone to report any adverse events, includ-
ing delayed healing or pain not controlled with over-the-counter
agents as described above. Most procedures lasted a total of 45–
60 minutes from the non-sterile scout imaging to the patient
departing the procedure room. Patients did not require conscious
sedation and were sent home immediately with no postprocedure
observation or recovery period and no activity restrictions.
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Tolerability. Tolerability of the procedure was assessed
by questionnaires administered before and after the proce-
dure as previously described (36). Patients were asked to rate
pain, swelling, and stiffness on a 10-point visual analog scale
(VAS). After the procedure, patients were also asked by ques-
tionnaire to rate their discomfort during the procedure (none,
mild, moderate, or severe) and to rate their likelihood to
agree to undergo another procedure (very likely, somewhat
likely, unsure, somewhat unlikely, or very unlikely).
Tissue preparation and flow cytometric analysis. From
the 12 pieces of synovial tissue obtained per patient by needle
biopsies, 4 were selected at random and placed into 10% neu-
tral buffered formalin for histologic analysis, 4 more randomly
selected pieces were placed into RNAlater (Ambion) for whole
tissue processing, and the remaining 4 were placed into PBS for
tissue digestion. Osteoarthritis (OA) synovial tissue was
received from the National Disease Research Interchange and
was shipped in Dulbecco’s modified Eagle’s medium and
antibiotics overnight on wet ice. Only soft tissues containing
meniscus and synovium were processed. OA synovial tissue was
processed identically to tissue from patients with RA.
The length of digestion (30–60 minutes) and intensity of
mechanical disaggregation before and after incubation were var-
ied to optimize macrophage isolation. Mechanical disaggrega-
tion was performed on a gentleMACS Dissociator (Miltenyi
Biotec). The pre-set gentleMACS programs m_lung_01 and
m_brain_01 were used to test moderate and aggressive mechani-
cal disaggregation, respectively. Sorted macrophages used for
analysis were processed by infusing tissue with a digestion buffer
(RPMI 1640 [Sigma], Liberase TL [0.1 mg/ml; Roche], and
DNase [0.1 mg/ml; Roche]) and minced with scissors. Tissue sus-
pensions were transferred to C-tubes (Miltenyi Biotec) and incu-
bated for 1 hour at 37°C with aggressive disaggregation before
and after incubation. The digestion reaction was quenched with
magnetic-activated cell sorter (MACS) buffer (Miltenyi Biotec),
and the tissue suspension was filtered over a 40-micron filter.
Red blood cells were lysed (BD Pharm Lyse) and then washed
twice with Hanks’ balanced salt solution (Thermo Fisher). Cells
were counted (Invitrogen Countess) and stained with a viability
dye (0.5 ll/ml for 15 minutes at 25°C in the dark) (data are avail-
able upon request from the corresponding author). Cells were
then washed twice with MACS buffer, incubated with Fc block
(BD Biosciences) (6 ll/60 ll total volume; maximum of 5 9 106
cells for 15 minutes at 4°C in the dark), stained with antibody
cocktail (for 30 minutes at 4°C in the dark) (data are available
upon request from the corresponding author), washed twice,
resuspended in MACS buffer, and kept on ice until sorted.
Synovial macrophages (CD45+, CD11b+, HLA–DR+,
CD15, CD1c, CD206+) were sorted on a BD FACSAria Sorp
instrument (BD Biosciences) at the Northwestern University
Robert H. Lurie Comprehensive Cancer Center Flow Cytometry
Core Facility. Cells from RA synovial biopsies were sorted
directly into 100 ll PicoPure RNA extraction buffer (Arcturus
Bioscience). Cells (>10,000) from OA tissues were sorted into
cold MACS buffer (Miltenyi Biotec) and immediately cen-
trifuged at 4°C. Supernatant was removed, and cells were resus-
pended in 100 ll PicoPure RNA extraction buffer. All cells were
stored at 80°C until RNA was extracted.
Histopathologic and immunohistochemical analysis. The
4 biopsy pieces fixed in 10% neutral buffered formalin for histo-
logic analysis were stored overnight and submitted to the Pathol-
ogy Core Facility at Northwestern University. Paraffin-embedded
tissue sections were stained with hematoxylin and eosin (H&E)
and for CD45 or CD68. Slide images were taken at 409 and 1009
magnification using an Olympus BX41 microscope and Olympus
DP21 camera. Since not all samples subjected to this procedure
demonstrate synovial lining, other characteristics including CD45
and CD68 staining were included to provide a semiquantitative or
qualitative analysis of inflammation in the biopsied tissue. RA sy-
novial biopsy sections stained with H&E or with antibodies to
either CD45 or CD68 antigens were scored for the percent sy-
novium of all 4 pieces of tissue. The CD45 and CD68 scores were
determined using a modified scoring system of 0–4 that indicates
the percent of CD45 or CD68 positivity in identified synovium
(35). All scoring was performed by an experienced rheumatologist
(RMP) who was blinded with regard to the origin of the samples.
Preparation of the RNA library. RNA was isolated from
whole synovial tissue by homogenizing tissue with 3.0 mm of high-
impact zirconium beads and a BeadBlaster 24 microtube homoge-
nizer (Benchmark Scientific). RNA was extracted from the cell
homogenate using a Qiagen Plus Mini kit. RNA from sorted
macrophages was extracted using a PicoPure RNA isolation kit
according to the instructions of the manufacturer (Arcturus).
RNA quality and quantity were measured using a High-Sensitivity
RNA ScreenTape System (Agilent Technologies). Whole synovial
tissue RNA-seq libraries were prepared from 90 ng of total RNA
using a NEBNext Ultra Kit with poly(A) enrichment. RNA-seq
libraries from sorted macrophage populations were prepared
using a SMART-Seq v4 Ultra Low Input RNA Kit (Clontech Lab-
oratories) followed by Nextera XT protocol (Illumina). RNA-seq
libraries were sequenced on a NextSeq 500 instrument (Illumina)
with ~5–109106 aligned reads per sample. A commercially avail-
able universal human RNA reference was prepared along with
the synovial RNA to represent background RNA expression.
RNA-seq analysis. RNA-seq data were de-multiplexed
using bcl2fastq, and RNA-seq reads were aligned to the human
reference genome (NCBI, hg19) using TopHat2 (version
2.17.1.14) aligners (52). Gene coverage of samples was calcu-
lated using the RSeQC package (53). Sample complexity was
calculated using the samtools makeTagDirectory command and
identifying the uniquely aligned positions compared to the num-
ber of aligned reads. Normalized gene counts were calculated
using HTSeq (54). For our analysis, we focused on genes in
which at least 2 samples had log2 (fragments per kilobase per
million [FPKM]) expression >3. For visualization, GENE-E soft-
ware (https://software.broadinstitute.org/GENE-E/) was used to
generate Pearson’s pairwise correlation matrices and to perform
K-means and hierarchical clustering. Differential gene expres-
sion between RA and OA samples in the whole tissue data set
was determined using the edgeR Bioconductor package parame-
ters as previously described (adjusted P < 0.01) (55,56). Gene
Ontology (GO) associations were determined by GOrilla (57).
To account for the increased noise of the low-input macrophage-
specific RNA-seq, we focused our analysis on genes in which at
least 2 samples had log2(FPKM + 1) expression >5, and lower
values were set to 5. We defined differentially expressed genes
across patients with RA as those with an adjusted range (log2
fold change between the second highest and second lowest sam-
ples) >1. We removed genes driven by 1 outlier sample (defined
as genes where the difference between the maximum and second
highest values was greater than the difference between the sec-
ond highest and second lowest values), leaving 553 genes for the
analysis. Modules were identified by clustering genes using K-
means clustering and calculating pairwise Pearson’s correlation
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between each gene. The enrichment or depletion of modules
within each patient was determined by a Kolmogorov-Smirnov
test comparing the expression level of genes in a given module to
all 553 genes (with P values less than 0.05 considered significant).
Statistical analysis. Associations between RNA-seq
expression patterns in patients and clinical parameters, including
disease duration, swollen joint count (SJC), tender joint count
(TJC), early disease (defined as a disease duration of <2 years),
rheumatoid factor (RF), anti–cyclic citrullinated peptide (anti-
CCP) antibodies, and history of treatment with biologic agents or
methotrexate, were determined (Table 1). Disease duration, SJC,
and TJC were recorded as continuous variables. Early disease, RF,
anti-CCP antibodies, and patient medication history were recorded
as categorical data (either positive or negative). Patients were
divided into 2 groups based on global gene expression data, and
associations of patient treatment and clinical data with group 1
and group 2 were determined using Fisher’s exact test for categori-
cal variables and Student’s t-test for continuous variables. Pearson’s
correlation was used to determine the association between the
patient’s median gene expression for each module and continuous
variables. The log2 fold change of the average median module
expression between patients with a positive value and those with a
negative value was used to calculate associations with categorical
variables (data are available upon request from the corresponding
author). Significant changes in gene expression were determined
using Student’s t-test.
RESULTS
Patient demographics. The REASON consor-
tium was created to adopt ultrasound-guided synovial
biopsy for research purposes in the US. Over 2 years,
we recruited 41 patients with RA from REASON sites
for ultrasound-guided synovial biopsies. Patient demo-
graphics, clinical data, and other pertinent information
are presented in Table 1.
Table 1. Patient characteristics and sample data*
Patient characteristics Histologic findings in RA synovial biopsy
specimens, mean  SEM (n = 30)‡
Age, years (n = 41) 57.5  11.4 % synovial tissue 36.0  5.6
Sex, no. (%) female/male 29 (71)/12 (29) CD45 score (range 0–4) 1.7  0.2
Disease duration, years (n = 40) 9.3  8.4 CD68 score (range 0–4) 1  0.1
Early disease, no. (%) (n = 40)† 9 (23) RNA sequencing data, mean  SEM
Rheumatoid factor positive,
no. (%) (n = 40)
23 (58) Whole tissue samples (n = 9 RA and 9 OA)
Anti-CCP positive, no. (%) (n = 36) 19 (53)
RIN
ESR, mm/hour (n = 14) 33.5  21.7
RA 6.7  0.5
DAS28 (n = 17) 4.7  1.3
OA 8.0  0.2
CDAI (n = 20) 21.5  10.6
Number of aligned reads, million
RAPID3 (n = 25) 11.4  7.4
RA 9.2  0.7
PGA (n = 24) 4.7  3.1
OA 12.9  1.1
HAQ (n = 18) 0.7  0.5
% of total reads aligned
TJC (n = 31) 5.8  6.0
RA 81.9  1.2
SJC (n = 31) 7.1  4.9
OA 85.3  1.2
Treatment, no. (%) (n = 31)
% complexity
No treatment 3 (10)
RA 54.8  1.7
Methotrexate
OA 56.2  1.9
Current 15 (48)
Sorted macrophage samples (n = 15 RA and 9 OA)
Past 9 (29)
Cells sorted
TNF inhibitor
RA 1,642  1,178
Current 12 (38)
OA 77,414  26,413
Past 17 (55)
Number of aligned reads, million
IL-6 inhibitor
RA 21.0  4.2
Current 2 (6)
OA 21.1  6.8
Past 2 (6)
% of total reads aligned
JAK inhibitor
RA 53.9  6.0
Current 3 (10)
OA 65.2  1.5
Past 5 (16)
% complexity
Other treatment
RA 37.2  2.7
Current 11 (35)
OA 38.1  2.2
Past 12 (39)
Prednisone <5 mg, current 1 (3)
Prednisone 5–10 mg, current 6 (19)
* Except where indicated otherwise, values are the mean  SD. Anti-CCP = anti–cyclic citrullinated peptide; ESR = erythrocyte sedimentation
rate; DAS28 = Disease Activity Score in 28 joints; CDAI = Clinical Disease Activity Index; RAPID3 = Routine Assessment of Patient Index Data
3; PGA = physician’s global assessment; HAQ = Health Assessment Questionnaire; TJC = tender joint count; SJC = swollen joint count; TNF =
tumor necrosis factor; IL-6 = interleukin-6; RA = rheumatoid arthritis; OA = osteoarthritis; RIN = RNA integrity number.
† Disease duration of <2 years.
‡ All slides were scored by the same physician (RMP), who was blinded with regard to the origin of the samples. The amount of synovial tissue in
each biopsy specimen was estimated by analysis of structure, lining, and leukocyte content.
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Safety and tolerability of ultrasound-guided sy-
novial biopsy. Real-time ultrasound images were used to
guide placement of the needle device for biopsy within the
synovium of the dorsal side of the wrist (Figures 1A and
B). Thirty-one of the 41 patients responded with complete
preprocedure and postprocedure VAS assessments of pain,
stiffness, and swelling of the biopsied wrist. There were no
differences between the preprocedure and postprocedure
scores in these patients (Figure 1C). Patients were then
asked to rate their likelihood of agreeing to repeat the
procedure, and 90.3% of the patients reported that they
would be very likely or somewhat likely to repeat the
biopsy, while only 6.5% stated that they would be some-
what or very unlikely to have a repeat biopsy (Figure 1C).
Histologic assessment of synovial tissue. The
quality of the synovial biopsy specimens obtained from
patients with RA was first quantified by histologic assess-
ment of tissue structure, presence of synovial lining, and
leukocytes (Table 1 and Figures 1D and E). Importantly,
all but 5 samples contained synovial tissue (>10%), and
Figure 1. Acquisition and analysis of synovial tissue from patients with rheumatoid arthritis (RA). A, Ultrasound-guided synovial biopsy of an
inflamed wrist using an 18-gauge 9 1.5-inch needle. B, Dorsal transverse (axial) view of a right wrist showing a needle track created with a 25-
gauge 9 1.5-inch needle (arrowheads) and a left wrist in which an 18-gauge 9 9-cm needle biopsy device has been introduced into the needle
track with a 10-mm throw opened (second and third arrowheads from the left). SV = superficial vein; Ext Tend = extensor tendon complex; Car-
pals = proximal row of carpal bones. C, Top, Patient-reported pain, stiffness, and swelling before and after the biopsy procedure on a visual analog
scale (VAS) of 1–10. Bars show the mean  SEM. Bottom, Patient-reported likelihood of agreeing to a subsequent procedure. VL = very likely;
SL = somewhat likely; NS = not sure; SU = somewhat unlikely; VU = very unlikely. D, Removal of synovial tissue from the biopsy device. Tissue
was placed into phosphate buffered saline on ice until processed. E, Histomorphologic features of synovial biopsy specimens obtained from 2 rep-
resentative RA patients. Representative photomicrographs of sections stained with hematoxylin and eosin (H&E), anti-CD45 (for hematopoietic
cells), and anti-CD68 antibodies (for macrophages) are shown. HS07 = human sample 07.
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11 biopsy specimens contained ≥50% synovial tissue.
The abundance of CD45-positive and CD68-positive
cells in each sample was scored on a modified scale of 0–
4 (35), revealing a substantial enrichment of hematopoi-
etic cells and, more specifically, macrophages in most
biopsy samples (Table 1).
RNA-seq analysis of whole tissue synovial biopsy
specimens. The fidelity of the complementary DNA
library created from whole synovial tissue obtained from
RA synovial biopsy specimens or from OA patients fol-
lowing whole joint replacement was assessed by a variety
of criteria (Table 1). The quality of the RNA-seq data for
whole tissue samples was determined by plotting the num-
ber of detectable genes at varying FPKM thresholds
across samples. There was no observable difference
between the number of genes expressed in RA versus OA
samples (Figure 2A). The read density over the length of
genes revealed that all samples had comparable coverage
Figure 2. Analysis of whole tissue RNA sequencing libraries. A, Number of genes with an expression level greater than a given log2 (fragments
per kilobase per million [FPKM]) value for each osteoarthritis (OA), rheumatoid arthritis (RA), and universal human RNA (uhRNA) control sam-
ple. B, Gene coverage plot displaying the average read density across genes from 50 to 30. C, Pairwise Pearson’s correlations of gene expression
between individual patient samples. Samples are organized by hierarchical clustering based on their Pearson’s correlation coefficients (corr. coeff.)
across samples. Numbers to the right of the matrix are the patient numbers for each sample. HS21 = human sample 21. D, Venn diagram of the
genes expressed in RA and OA samples. The differential analysis (adjusted P < 0.01) revealed 411 and 330 genes that were preferentially
expressed in RA and OA tissue, respectively. Select processes from gene ontology (GO) enrichment analysis of genes preferentially expressed in
each tissue type are listed. E, Normalized gene expression of individual genes in RA versus OA samples. Symbols represent individual samples;
horizontal lines and error bars show the median and interquartile range. * = adjusted P < 0.01.
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Figure 3. Isolation of synovial macrophages and macrophage-specific RNA sequencing. A, Gating strategy used to identify synovial macrophages
in osteoarthritis (OA) and rheumatoid arthritis (RA) tissue. DC = dendritic cell. B, Optimization of the synovial tissue processing procedure. The
success of tissue processing was evaluated by the number of viable, CD45+, and CD11b+ cells identified by flow cytometry. C, Number of genes
with an expression level greater than a given log2 (fragments per kilobase per million [FPKM]) value for each OA, RA, and universal human
RNA (uhRNA) control sample. D, Gene coverage plot displaying the average read density across genes from 50 to 30. E, Log2 fold change of gene
expression between RA and OA whole tissue samples and macrophages. Broken lines indicate a difference of 1; solid line indicates no change in
expression. Select genes are displayed. F, Venn diagram comparing numbers of genes expressed in sorted macrophages and whole tissue. G, Num-
bers of genes differentially expressed in whole tissue that were also detected in sorted macrophages from RA and OA samples. H, Log2 fold
change in expression of the 467 differentially expressed genes (in G) in whole tissue and sorted macrophages. Genes are ordered along the x-axis
by decreasing fold change in whole tissue. The numbers of genes preferentially expressed in RA tissue (log2 fold change >1) and OA tissue (log2
fold change <1) are indicated in red and blue, respectively.
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across the genome (Figure 2B). Nine RA synovial biopsy
samples and 9 OA tissue samples produced high-quality
RNA-seq libraries and were used for further analyses, con-
centrating on a set of 9,366 expressed genes. The global
gene expression profiles from synovial tissue samples were
heterogeneous across the RA samples and did not clearly
cluster apart from the OA samples (Figure 2C). The vari-
ability among patients highlights the complexity in the pre-
sentation of RA in whole tissue and points to a shift in gene
expression in individual cell types that could be associated
with disease activity status and therapy at the time of biopsy.
Differential expression analysis identified genes that
were specific to either RA or OA synovial tissue samples.
We found 411 RA-specific genes and 330 OA-specific
genes (Figure 2D). GO analysis revealed that RA-specific
genes were associated with a wide range of immune pro-
cesses, including leukocyte activation, Tcell activation, and
B cell–mediated immunity, while OA-specific genes were
associated with more homeostatic processes, such as osteo-
blast differentiation, bone remodeling, and the epidermal
growth factor receptor signaling pathway. Specifically, we
found several macrophage-related genes (FCGR2A, IRF8,
MyD88, and CD14) that were significantly up-regulated in
RA relative to OA synovial tissue (Figure 2E). Genes that
were preferentially expressed in OA, such as lubricin (58),
JUN (59), ADAMTS1 (60), and SCRG1 (61), have previ-
ously been linked to differences in synovial tissue function
in OA. The broad range of pathways involved in RA at the
level of whole tissue highlights the need for a cell type–
specific approach to better understand the role of particu-
lar cell populations.
Synovial macrophage digestion and RNA-seq
analysis. Multiparameter flow cytometry was used to iso-
late macrophages from RA and OA synovial tissue (Fig-
ure 3A). Macrophages were gated via the inclusion of
singlets, viable, CD45+, and HLA–DR+ cells. Macro-
phages were further isolated by excluding dendritic cells
and then gating on the remaining HLA–DR+ cells fol-
lowed by CD11b+ cells to identify the CD206+ macro-
phage populations. An optimized digestion protocol was
developed to isolate viable macrophages from synovial tis-
sue. The effectiveness of tissue digestion was assessed by
maximizing the number of viable, CD45+, and CD11b+
cells within a given single-cell suspension (Figure 3B). A
mean  SEM of 1,642  1,178 macrophages was isolated
from digested biopsy samples and prepared for RNA-seq
analysis (Table 1). An identical digestion protocol was
used to isolate cell populations from OA synovial tissue as
Figure 4. Analysis of global gene expression profiles in sorted macrophages from patients with rheumatoid arthritis. A, Pairwise Pearson’s correla-
tion of gene expression between individual patient samples. Samples are organized by hierarchical clustering based on their Pearson’s correlation
coefficients (corr. coeff.) across samples, forming 2 groups. HS20 = human sample 20. B, Table of association analysis of group 1 and group 2 (as
defined in A) with clinical parameters. Values reflect either the group average (for continuous variables) or percent of patients (for categorical
variables). P values for disease duration, swollen joint count (SJC), and tender joint count (TJC) were determined by Student’s t-test, and P values
for early disease, rheumatoid factor, anti–cyclic citrullinated peptide (anti-CCP) antibody, and treatment status were determined by Fisher’s exact
test. Significant values are shown in red.
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described above, resulting in an average of 77,414 macro-
phages per sample (Table 1).
Isolated macrophages from 15 RA biopsy sam-
ples and 9 OA tissue samples were collected and passed
sequencing quality control for further analysis. The per-
cent alignment of reads (average 54%) was lower than
in whole tissue (average 82%) likely due to the
increased noise of low input. There was a minimal dif-
ference in the number of genes detected in RA versus
OA macrophages (Figure 3C). RA macrophages demon-
strated comparable complexity (Table 1) and gene cover-
age (Figure 3D) to OA samples even though the
number of RA macrophages was 45 times less than the
number of sorted OA macrophages.
To determine whether RNA-seq data from macro-
phages provided additional information that could not be
gleaned from the whole tissue data, we investigated
the “macrophage-specific” gene expression profiles. A
comparison of fold change in gene expression between
RA and OA revealed differentially expressed genes that
were detected only by whole tissue or only by macro-
phage-specific RNA-seq (Figure 3E). For example, genes
associated with inflammatory arthritis, such as PI3 (62)
and MMP3 (63), were preferentially expressed in RA and
OA macrophages, respectively, while no change in expres-
sion was observed in whole tissue RNA-seq. Further com-
parison revealed that 6,414 genes were expressed in both
data sets, while 2,952 genes were exclusively found in
whole tissue, and 2,116 genes were macrophage specific
(Figure 3F). Genes exclusively expressed by whole tissue
were likely associated with other cell types, while macro-
phage-specific genes were likely below the limit of detec-
tion of whole tissue RNA-seq. Of the 411 RA-specific and
330 OA-specific genes from whole tissue (Figure 2D), 315
and 152, respectively, were expressed in the macrophage-
specific data set (Figure 3G). However, many of these 467
genes were not differentially expressed in the same direc-
tion in the macrophage-specific data set (Figure 3H).
Next, we compared the global gene expression pro-
files from synovial macrophages across patients. We identi-
fied 2 distinct groups of RA patients based on gene
expression profiles (Figure 4A). Group 1 consisted of two-
thirds of the patients (10 of 15) with highly similar gene
expression profiles, while group 2 contained the remaining
5 patients with divergent gene expression. Patients in
group 2 exhibited significantly higher SJC than those in
group 1 (P = 0.03). These findings demonstrate the possi-
bility for cell type–specific transcriptional profiles of RA
patients to provide information about disease severity.
Modules of co-regulated genes may represent
pathways that perform specific functions in disease. To
identify gene modules within the macrophage
transcriptional profiles, we defined a subset of 553 genes
as differentially expressed across 15 RA patients after
accounting for noise and outliers (see Patients and Meth-
ods). These genes were clustered into 6 modules (mod-
ules 1–6) based on the similarity in their patterns of
expression across patients (Figure 5A). We calculated the
enrichment or depletion of each gene module within the
expression profile of each patient to determine which
patients were driving these modules (Figure 5B).
Despite the limited statistical power of a sample
set of 15 patients, we were able to identify associations
between the expression of these gene modules in patients
and clinical parameters (Figures 5C and D). For example,
expression levels of module 2 genes, including CCR1 and
TREM2 (Figure 5E), were significantly increased (1.31
fold or 0.39 log2 fold change; P = 0.05) (Figure 5D) in
patients who had stopped taking methotrexate. In addi-
tion, expression levels of genes in module 3 were nega-
tively correlated with disease severity as measured by SJC
(P = 0.007) and had 1.7-fold higher expression in patients
recently diagnosed as having RA (log2 fold change = 0.78;
P = 0.04) (Figure 5D). Module 3 genes, such as NFKB1A
and TIMP1, are involved in the cellular response to IL-1
as determined by GO enrichment (data are available
upon request from the corresponding author). Module 4
genes were 1.7-fold more highly expressed in patients who
were not taking a biologic medication at the time of
biopsy (log2 fold change = 0.78; P = 0.01). Module 4 was
enriched with immune response genes such as TNF and
MAFB (Figure 5E). Expression of module 5 genes, such
as MIF and HMGB2, was positively associated with dis-
ease severity as measured by TJC (P = 0.03) (Figure 5C).
Genes in module 6, such as CD83 and CXCR4, were 2.0-
fold higher in patients who were negative for RF (log2
fold change = 1.0; P = 0.03). Taken together, our
data demonstrate for the first time that transcriptional
profiling of isolated synovial macrophages obtained using
ultrasound-guided synovial biopsies may be used to
characterize patients in a biologically relevant manner.
DISCUSSION
Recent advances in ultrasound technology have
opened up a new opportunity for rheumatologists to per-
form minimally invasive ultrasound-guided synovial tissue
biopsies (25). While arthroplasty allows for the collection
of large pieces of synovial tissue, using it as a method of
obtaining tissue from RA patients for research purposes in
the US and in a longitudinal manner is challenging
(23,29,41,45,64–67). Moreover, the tissue obtained from
arthroplasty is usually late stage and may not reflect
ongoing active disease, unlike tissue which may be obtained
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using ultrasound-guided synovial biopsy. The fact that
ultrasound-guided synovial biopsies may be performed in
the clinic without a surgical suite and require minimal to no
recovery time for the patient outweighs the smaller amount
of tissue retrieved (23,29,41,45,64–67). In fact, in several
countries in Europe, this technique is used to obtain sy-
novial tissue for research purposes in a large number of
patients without significant complications (34–36,38–40,68–
73). The procedure itself is well accepted by both patients
and referring rheumatologists in the US, at rates similar to
those observed by our European colleagues (34,36).
Previous studies have focused on access to the
joint, intrajoint synovial variation, and reproducibility of
measurements using the ultrasound-guided synovial
biopsy technique (34–36). Furthermore, these biopsies do
not appear to affect subsequent clinical or ultrasound dis-
ease activity assessments, which is important for patients
who might subsequently enroll in clinical trials (74). Euro-
pean groups have also performed numerous studies to
validate the needle biopsy and portal and forceps proce-
dures and tissue sampling (34–36,38–40,68,75,76). Our
data demonstrate that the ultrasound-guided synovial tis-
sue biopsy specimens obtained from patients with RA are
sufficient for RNA-seq, distinguish differences between
patients with RA and those with OA, and, importantly,
set the framework for the stratification of patients with
RA according to the most prominent disease pathway.
We also report an optimized digestion protocol for syno-
vial tissue obtained by ultrasound-guided biopsies and
demonstrate the ability to sort viable hematopoietic cells
Figure 5. A, Pairwise Pearson’s correlations between 553 differentially expressed genes across sorted macrophages from rheumatoid arthritis (RA)
patients. Genes were clustered using K-means clustering, and 6 modules (mod) of co-regulated genes were identified. B, Expression of genes in
each module in each patient. The Kolmogorov-Smirnov test was used to determine if genes were enriched or depleted (P < 0.05). C, Table of asso-
ciation displaying Pearson’s correlations between the median expression of gene modules in patients and the given clinical parameters (continuous
variables). Correlation coefficients (corr. coeff.) with a P value less than 0.05 are shown in boldface. D, Table of association displaying the average
fold change (log2 fold change) between the median expression of gene modules in patients who were positive versus those who were negative for
the indicated clinical parameters (categorical variables). Current treatment compares patients who were receiving the medication at the time of
biopsy with those who were not receiving the medication at the time of biopsy. Past treatment compares patients who had stopped the medication
with those who had never received the medication. Significant comparisons (P < 0.05, by t-test) are shown in boldface. E, Expression levels (frag-
ments per kilobase per million [FPKM]) of individual genes selected across the 6 modules in patients with RA. HS20 = human sample 20; SJC =
swollen joint count; TJC = tender joint count; anti-CCP = anti–cyclic citrullinated peptide; MTX = methotrexate.
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by FACS. Further, we show that only small numbers of
cells (as few as 10 cells) are sufficient for generation of
libraries for quality RNA-seq analysis. With our initial
cohort of 41 patients, we have been able to link the cell
type–specific transcriptional signatures with patients’
treatment regimen and clinical information.
Currently, the standard of care for RA is to pre-
scribe biologic therapy through a costly and time-consum-
ing trial-and-error process. Therefore, the utility of a
biomarker to identify how a patient will respond to a par-
ticular therapy cannot be overstated. While peripheral
blood is attractive for identifying a potential biomarker due
to its ease of attainability, this approach has not been fruit-
ful. Early studies by Dr. Paul Tak and colleagues demon-
strated the potential of obtaining synovial tissue as a means
to determine a biomarker for responsiveness to therapy
(31). In his seminal studies, he showed that a reduction in
the number of synovial sublining macrophages correlates
with a decrease in disease activity (i.e., the Disease Activity
Score in 28 joints) (31). The abundance of synovial sublin-
ing macrophages is currently a leading candidate for a
viable biomarker of therapeutic response in RA (25).
We posit that transcriptional signatures in macro-
phages regardless of location (sublining versus synovial
lining) will predict responsiveness to specific non-biologic
and/or biologic therapies. Our data suggest the existence
of associations between the transcriptional signature of
macrophages and treatment course (or patient compli-
ance). However, the present study is limited in its ability
to predict response to therapy because of the constraint of
obtaining tissue at a single time point for each patient at
different stages of disease. Future studies beyond the
scope of the present one will entail collection of synovial
biopsy specimens from a larger cohort longitudinally, prior
to and following therapy. Therefore, this study serves as
proof of the principle that transcriptional analysis of syno-
vial macrophages using ultrasound-guided synovial biop-
sies may function to uncover novel pathways underlying
disease pathogenesis or response to therapy. Currently,
studies are also underway in the Accelerating Medicines
Partnership which will take advantage of synovial biopsies
for identification of molecular pathways (77).
In summary, this study is the first in the US to har-
ness the potential of ultrasound-guided synovial biopsies
as a method of obtaining synovial tissue from patients
with RA. Based on the recent success of REASON using
minimally invasive ultrasound-guided synovial biopsies,
coupled with our ability to interrogate synovial tissue at
multiple levels using cutting-edge technologies, we believe
that future studies have the potential to provide critical
information to rheumatologists in establishing precision
medicine as a reality for our patients.
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